Systemic JIA

Introduction

• Constitutes 5-15% of all juvenile idiopathic arthritis cases.
• Lacks specific sex predilection, affecting boys and girls equally.
• Peak age of onset typically 1-5 years.

Pathophysiology

Immune System Dysregulation

• Classified fundamentally as an autoinflammatory disorder.
• Primarily affects innate immune system rather than adaptive immunity.
• Lacks classic autoreactive T cells and autoantibodies.

Cytokine Profile

• Interleukin-1 (IL-1) family cytokines serve as key pathogenic drivers.
• Marked elevation in interleukin-6 (IL-6) drives systemic inflammatory manifestations.
• Interleukin-18 (IL-18) acts as central driver, showing significant serum elevation.

Clinical Manifestations

Systemic Features

• Fever: Intermittent, high-spiking quotidian fever exceeding 39°C. Peaks once or twice daily, typically evening. Rapid return to normal or subnormal baseline.
• Rash: Evanescent, salmon-pink, maculopapular eruptions. Distributed mainly over trunk and proximal extremities. Migratory, nonpruritic, transient lasting less than one hour. Demonstrates Koebner phenomenon, evoked by superficial trauma or heat.
• Visceral Involvement: Generalized lymphadenopathy, hepatosplenomegaly.
• Serositis: Pleuritis and pericarditis common; myocarditis rare.

Articular Features

• Arthritis often absent at initial presentation, developing later in disease course.
• Symmetrical polyarticular pattern common, affecting knees, wrists, ankles, cervical spine, hips.

Diagnostic Framework

Table 1: Classification Criteria For Systemic Juvenile Idiopathic Arthritis

Criterion Type	Specific Requirements
Mandatory	Arthritis in $\ge$ 1 joint with or preceded by documented quotidian fever $\ge$ 2 weeks (daily for $\ge$ 3 days)
Additive (Requires $\ge$ 1)	Evanescent erythematous rash
	Generalized lymph node enlargement
	Hepatomegaly or splenomegaly
	Serositis
Exclusions	Psoriasis in patient or first-degree relative
	HLA-B27 positive male onset > 6 years
	Ankylosing spondylitis, enthesitis-related arthritis, inflammatory bowel disease in relative
	Positive IgM rheumatoid factor twice, 3 months apart

Laboratory Investigations

Inflammatory Markers

• Extreme leukocytosis featuring neutrophilia.
• Marked thrombocytosis.
• Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
• Severe hyperferritinemia.
• Elevated serum S100A8, S100A9, and S100A12 levels.

Hematologic And Immunologic Profile

• Microcytic anemia secondary to severe inflammation-induced iron sequestration.
• Rheumatoid factor (RF) and antinuclear antibodies (ANA) classically negative.

Severe Complications

Macrophage Activation Syndrome

• Life-threatening complication occurring in 5-8% of cases overtly, subclinical in up to 30%.
• Driven by excessive activation of macrophages and T lymphocytes.
• Clinical shift: Fever becomes unremitting.
• New onset central nervous system encephalopathy.
• Dramatic laboratory shift: Sudden drop in erythrocyte sedimentation rate (ESR) due to hypofibrinogenemia.
• Rapid development of pancytopenia (leukopenia, thrombocytopenia) replacing previous elevations.
• Extreme hyperferritinemia (>10,000 ng/mL), hypertriglyceridemia, elevated hepatic transaminases.

Inflammatory Lung Disease

• Rare, potentially fatal complication.
• Predominant pathology features pulmonary alveolar proteinosis and endogenous lipoid pneumonia.
• Associated with younger age onset, prior macrophage activation syndrome, and high IL-18.

Algorithmic Management

Table 2: Stepwise Pharmacotherapy For Systemic Juvenile Idiopathic Arthritis

Treatment Tier	Pharmacologic Agents	Indications & Efficacy
First Line	Nonsteroidal anti-inflammatory drugs (NSAIDs)	Initial symptomatic relief; rarely controls severe systemic disease alone.
Bridge / Severe	Systemic Corticosteroids	Controls severe systemic illness, macrophage activation syndrome. Avoid long-term use.
Targeted Biologics	IL-1 Inhibitors (Anakinra, Canakinumab)	Highly effective for profound systemic features; often initiates rapid remission.
Targeted Biologics	IL-6 Inhibitors (Tocilizumab)	Controls refractory systemic disease, normalizes acute phase reactants.
Conventional	Methotrexate	Adjunctive therapy primarily targeting persistent articular involvement.

• Tumor necrosis factor (TNF) inhibitors remain less effective for systemic symptoms compared to IL-1 and IL-6 blockade.
• Emergent intravenous methylprednisolone pulse therapy alongside cyclosporine required for macrophage activation syndrome.